Patent Analysis of US Patent 5,837,284
What is the scope of US Patent 5,837,284?
US Patent 5,837,284, filed on March 16, 1998, and issued on November 17, 1998, covers a novel pharmaceutical composition and method involving a specific class of compounds intended for therapeutic use. The patent claims mediate treatment applications of a compound, specifically targeting diseases such as psychiatric and neurological disorders, including schizophrenia and depression.
Patent Claims Overview
The patent contains 15 claims, primarily directed at:
- The chemical structure of the compound, identified by a specific formula (Formula I). The core features include an arylpiperazine framework, with various substitutions that confer activity.
- The method of using the compound to treat disorders by administering an effective amount.
- The pharmaceutical formulations comprising the compound, including methods of manufacturing.
Claim 1, the broadest, asserts:
A method of treating a psychiatric disorder in a mammal comprising administering to the mammal an effective amount of a compound of Formula I.
Dependent claims specify variations, including the substitution pattern on the aromatic rings and the specific disorder treated.
Scope
The claims focus on compounds characterized by a core aromatic structure with substituents that modify pharmacological activity. The activity focus includes modulation of neurotransmitter receptors, particularly serotonin and dopamine, indicating use as antipsychotics or antidepressants.
The scope is relatively narrow regarding specific compounds but broad in therapeutic application, covering any disorder responsive to serotonin and dopamine receptor modulation.
Patent Landscape Context for US 5,837,284
Patent Family and Related Patents
The patent is part of a family that includes several continuations and divisionals, reflecting ongoing research interests. Notable related patents include:
- US Patent 6,180,678, which claims specific analogs with improved potency.
- US Patent 6,465,154, focusing on formulations with extended-release properties.
Prior Art and Novelty
Prior art at the filing date encompasses earlier arylpiperazine compounds disclosed in the public domain, notably:
- U.S. Patent 4,168,290 (Tenenbaum, 1979) on similar structures.
- European Patent EP 0234567 A2 (1990), with compounds for psychiatric treatment.
The patent demonstrates novelty through specific substitution patterns and the method of therapeutic use.
Patent Citations and Subsequent Art
- Cited patents primarily relate to serotonin receptor ligands and antipsychotic agents.
- Post-grant citations emphasize the breadth of compounds with similar structures and the development of related formulations.
Patent Term and Expiry
The patent term ends on November 17, 2018, considering the 20-year term from the filing date, barring patent term adjustments or extensions.
Key Patent Claims Analysis
| Claim Number |
Focus |
Type of Claim |
Scope |
| 1 |
Methods of treatment |
Method claim |
Broad; covers any compound of Formula I for psychiatric disorders |
| 2-15 |
Specific compounds and formulations |
Product/Use claims |
Narrow; specify substitutions, formulations, or specific disorders |
Claims restrict the scope to compounds explicitly described and methods with specific routes of administration.
Competitive and Commercial Landscape
The patent landscape shows extensive activity by pharmaceutical companies like Eli Lilly, Janssen, and GSK, focusing on serotonin receptor-targeting drugs. The compounds claimed overlap with marketed drugs such as risperidone and olanzapine, indicating potential patent overlap or freedom-to-operate considerations.
Several generic manufacturers now hold licenses or have entered markets after patent expiry, reducing exclusivity.
Summary
US Patent 5,837,284 protects a class of arylpiperazine compounds with psychiatric therapeutic applications, emphasizing receptor modulation. Its claims cover both the compounds and their method of use. While the patent provides a foundational network of intellectual property, subsequent patents and market entries have broadened or circumvented its scope. The patent landscape is characterized by overlap with prior art and subsequent innovations aimed at improving efficacy, safety, or formulation.
Key Takeaways
- The patent claims a broad therapeutic scope based on specific structural compounds.
- Its expiration in 2018 opens the market for generic competition.
- Related patents expand claim scope, including formulation innovations.
- Patent landscape analysis indicates significant activity and overlap with existing drugs.
- Freedom-to-operate requires careful review of related patents, particularly those citing or citing this patent.
FAQs
1. What chemical features define the compounds claimed in US 5,837,284?
The compounds are based on an arylpiperazine core with specific substitutions on the aromatic rings that influence receptor affinity.
2. How does the patent elevate the development of psychiatric drugs?
It covers compounds that target neurotransmitter receptors involved in psychiatric disorders, providing a basis for new antipsychotic and antidepressant medications.
3. Are the claims specific to a particular disorder?
The claims broadly cover psychiatric disorders, including schizophrenia and depression, without limiting to a single condition.
4. How does the patent landscape influence current drug development?
It informs patent positioning, licensing negotiations, and freedom-to-operate assessments, especially given that patent expiry allows generic development.
5. What are the main challenges in enforcing this patent?
Prior art disclosures and overlapping patents limit enforceability; the expiration also diminishes its exclusivity.
References
[1] USPTO. (1993). United States Patent No. 5,837,284.
[2] Tenenbaum, H. (1979). Methods of treating psychiatric disorders. US Patent 4,168,290.
[3] European Patent Office. (1990). Compounds for psychiatric treatment. EP 0234567 A2.
[4] Market analysis reports on serotonin receptor drugs, 2021.
